{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T23:52:43Z","timestamp":1788652363629,"version":"build-2803163510"},"reference-count":72,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,2,24]],"date-time":"2023-02-24T00:00:00Z","timestamp":1677196800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,2,24]],"date-time":"2023-02-24T00:00:00Z","timestamp":1677196800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2023,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>There are currently three thrombopoietin receptor agonists (TPO-RAs) approved in Europe for treating patients with immune thrombocytopenia (ITP): romiplostim (Nplate\u00ae), eltrombopag (Revolade\u00ae), and avatrombopag (Doptelet\u00ae). However, comparative clinical data between these TPO-RAs are limited. Therefore, the purpose of this study was to perform a literature review and seek expert opinion on the relevance and strength of the evidence concerning the use of TPO-RAs in adults with ITP. A systematic search was conducted in PubMed and Embase within the last 10\u00a0years and until June 20, 2022. A total of 478 unique articles were retrieved and reviewed for relevance. The expert consensus panel comprised ITP senior hematologists from eight countries across Central Europe. The modified Delphi method, consisting of two survey rounds, a teleconference and email correspondence, was used to reach consensus. Forty articles met the relevancy criteria and are included as supporting evidence, including five meta-analyses analyzing all three European-licensed TPO-RAs and comprising a total of 31 unique randomized controlled trials (RCTs). Consensus was reached on seven statements for the second-line use of TPO-RAs in the management of adult ITP patients. In addition, the expert panel discussed TPO-RA treatment in chronic ITP patients with mild\/moderate COVID-19 and ITP patients in the first-line setting but failed to reach consensus. This work will facilitate informed decision-making for healthcare providers treating adult ITP patients with TPO-RAs. However, further studies are needed on the use of TPO-RAs in the first-line setting and specific patient populations.<\/jats:p>","DOI":"10.1007\/s00277-023-05114-8","type":"journal-article","created":{"date-parts":[[2023,2,24]],"date-time":"2023-02-24T10:02:42Z","timestamp":1677232962000},"page":"715-727","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Use of thrombopoietin receptor agonists in adults with immune thrombocytopenia: a systematic review and Central European expert consensus"],"prefix":"10.1007","volume":"102","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-3755-4477","authenticated-orcid":false,"given":"Dra\u017een","family":"Pulani\u0107","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0567-4250","authenticated-orcid":false,"given":"Angelika","family":"B\u00e1torov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4170-8577","authenticated-orcid":false,"given":"Imre","family":"Bod\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Libor","family":"\u010cervinek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0681-4198","authenticated-orcid":false,"given":"Ioana","family":"Ionita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2238-8598","authenticated-orcid":false,"given":"Toshko","family":"Lissitchkov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anahit","family":"Melikyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3987-3100","authenticated-orcid":false,"given":"Maria","family":"Podolak-Dawidziak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,2,24]]},"reference":[{"issue":"6","key":"5114_CR1","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1097\/moh.0b013e32833eaef3","volume":"17","author":"JW Semple","year":"2010","unstructured":"Semple JW, Provan D, Garvey MB, Freedman J (2010) Recent progress in understanding the pathogenesis of immune thrombocytopenia. Curr Opin Hematol 17(6):590\u2013595. https:\/\/doi.org\/10.1097\/moh.0b013e32833eaef3","journal-title":"Curr Opin Hematol"},{"key":"5114_CR2","doi-asserted-by":"publisher","unstructured":"Provan D, Semple JW (2022) Recent advances in the mechanisms and treatment of immune thrombocytopenia. eBioMedicine 76:103820.\u00a0https:\/\/doi.org\/10.1016\/j.ebiom.2022.103820","DOI":"10.1016\/j.ebiom.2022.103820"},{"issue":"10","key":"5114_CR3","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1056\/NEJMcp1810479","volume":"381","author":"N Cooper","year":"2019","unstructured":"Cooper N, Ghanima W (2019) Immune thrombocytopenia. N Engl J Med 381(10):945\u2013955. https:\/\/doi.org\/10.1056\/NEJMcp1810479","journal-title":"N Engl J Med"},{"issue":"3","key":"5114_CR4","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1002\/ajh.21616","volume":"85","author":"DR Terrell","year":"2010","unstructured":"Terrell DR, Beebe LA, Vesely SK, Neas BR, Segal JB, George JN (2010) The incidence of immune thrombocytopenic purpura in children and adults: a critical review of published reports. Am J Hematol 85(3):174\u2013180. https:\/\/doi.org\/10.1002\/ajh.21616","journal-title":"Am J Hematol"},{"issue":"20","key":"5114_CR5","doi-asserted-by":"publisher","first-page":"10918","DOI":"10.3390\/ijms222010918","volume":"22","author":"M Sobas","year":"2021","unstructured":"Sobas M, Podolak-Dawidziak M, Lewandowski K, Bator M, Wr\u00f3bel T (2021) Primary immune thrombocytopenia and essential thrombocythemia: so different and yet somehow similar-cases series and a review of the literature. Int J Mol Sci 22(20):10918. https:\/\/doi.org\/10.3390\/ijms222010918","journal-title":"Int J Mol Sci"},{"issue":"3","key":"5114_CR6","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1111\/ejh.13803","volume":"109","author":"IU Doobaree","year":"2022","unstructured":"Doobaree IU, Conway K, Miah H, Miah A, Makris M, Hill Q, Cooper N, Bradbury C, Newland A, Provan D, McDonald V, registry UaI (2022) Incidence of adult primary immune thrombocytopenia in England\u2014an update. Eur J Haemat 109(3):238\u2013249. https:\/\/doi.org\/10.1111\/ejh.13803","journal-title":"Eur J Haemat"},{"issue":"21","key":"5114_CR7","doi-asserted-by":"publisher","first-page":"2829","DOI":"10.1182\/blood-2017-03-754119","volume":"129","author":"MP Lambert","year":"2017","unstructured":"Lambert MP, Gernsheimer TB (2017) Clinical updates in adult immune thrombocytopenia. Blood 129(21):2829\u20132835. https:\/\/doi.org\/10.1182\/blood-2017-03-754119","journal-title":"Blood"},{"issue":"1 Suppl 2","key":"5114_CR8","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1053\/j.seminhematol.2008.12.005","volume":"46","author":"DB Cines","year":"2009","unstructured":"Cines DB, Liebman H, Stasi R (2009) Pathobiology of secondary immune thrombocytopenia. Semin Hematol 46(1 Suppl 2):S2\u2013S14. https:\/\/doi.org\/10.1053\/j.seminhematol.2008.12.005","journal-title":"Semin Hematol"},{"issue":"1","key":"5114_CR9","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1172\/jci113060","volume":"80","author":"PJ Ballem","year":"1987","unstructured":"Ballem PJ, Segal GM, Stratton JR, Gernsheimer T, Adamson JW, Slichter SJ (1987) Mechanisms of thrombocytopenia in chronic autoimmune thrombocytopenic purpura. Evidence of both impaired platelet production and increased platelet clearance. J Clin Invest 80(1):33\u201340. https:\/\/doi.org\/10.1172\/jci113060","journal-title":"J Clin Invest"},{"issue":"3","key":"5114_CR10","doi-asserted-by":"publisher","first-page":"433","DOI":"10.7326\/0003-4819-38-3-433","volume":"38","author":"WJ Harrington","year":"1953","unstructured":"Harrington WJ, Sprague CC, Minnich V, Moore CV, Aulvin RC, Dubach R (1953) Immunologic mechanisms in idiopathic and neonatal thrombocytopenic purpura. Ann Intern Med 38(3):433\u2013469. https:\/\/doi.org\/10.7326\/0003-4819-38-3-433","journal-title":"Ann Intern Med"},{"issue":"10","key":"5114_CR11","doi-asserted-by":"publisher","first-page":"e5849","DOI":"10.7759\/cureus.5849","volume":"11","author":"M Samson","year":"2019","unstructured":"Samson M, Fraser W, Lebowitz D (2019) Treatments for primary immune thrombocytopenia: a review. Cureus 11(10):e5849\u2013e5849. https:\/\/doi.org\/10.7759\/cureus.5849","journal-title":"Cureus"},{"issue":"22","key":"5114_CR12","doi-asserted-by":"publisher","first-page":"3780","DOI":"10.1182\/bloodadvances.2019000812","volume":"3","author":"D Provan","year":"2019","unstructured":"Provan D, Arnold DM, Bussel JB, Chong BH, Cooper N, Gernsheimer T, Ghanima W, Godeau B, Gonz\u00e1lez-L\u00f3pez TJ, Grainger J, Hou M, Kruse C, McDonald V, Michel M, Newland AC, Pavord S, Rodeghiero F, Scully M, Tomiyama Y, Wong RS, Zaja F, Kuter DJ (2019) Updated international consensus report on the investigation and management of primary immune thrombocytopenia. Blood Adv 3(22):3780\u20133817. https:\/\/doi.org\/10.1182\/bloodadvances.2019000812","journal-title":"Blood Adv"},{"issue":"23","key":"5114_CR13","doi-asserted-by":"publisher","first-page":"3829","DOI":"10.1182\/bloodadvances.2019000966","volume":"3","author":"C Neunert","year":"2019","unstructured":"Neunert C, Terrell DR, Arnold DM, Buchanan G, Cines DB, Cooper N, Cuker A, Despotovic JM, George JN, Grace RF, K\u00fchne T, Kuter DJ, Lim W, McCrae KR, Pruitt B, Shimanek H, Vesely SK (2019) American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Adv 3(23):3829\u20133866. https:\/\/doi.org\/10.1182\/bloodadvances.2019000966","journal-title":"Blood Adv"},{"issue":"11","key":"5114_CR14","doi-asserted-by":"publisher","first-page":"2386","DOI":"10.1182\/blood-2008-07-162503","volume":"113","author":"F Rodeghiero","year":"2009","unstructured":"Rodeghiero F, Stasi R, Gernsheimer T, Michel M, Provan D, Arnold DM, Bussel JB, Cines DB, Chong BH, Cooper N, Godeau B, Lechner K, Mazzucconi MG, McMillan R, Sanz MA, Imbach P, Blanchette V, K\u00fchne T, Ruggeri M, George JN (2009) Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood 113(11):2386\u20132393. https:\/\/doi.org\/10.1182\/blood-2008-07-162503","journal-title":"Blood"},{"issue":"1","key":"5114_CR15","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1182\/asheducation-2017.1.400","volume":"2017","author":"CE Neunert","year":"2017","unstructured":"Neunert CE (2017) Management of newly diagnosed immune thrombocytopenia: can we change outcomes? Hematology Am Soc Hematol Educ Program 2017(1):400\u2013405. https:\/\/doi.org\/10.1182\/asheducation-2017.1.400","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"6","key":"5114_CR16","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1002\/ajh.24702","volume":"92","author":"G Moulis","year":"2017","unstructured":"Moulis G, Germain J, Comont T, Brun N, Dingremont C, Castel B, Arista S, Sailler L, Lapeyre-Mestre M, Beyne-Rauzy O, Godeau B, Adoue D, Group TCI (2017) Newly diagnosed immune thrombocytopenia adults: clinical epidemiology, exposure to treatments, and evolution. Results of the CARMEN multicenter prospective cohort. Am J Hematol 92(6):493\u2013500. https:\/\/doi.org\/10.1002\/ajh.24702","journal-title":"Am J Hematol"},{"key":"5114_CR17","unstructured":"European Medicines Agency (EMA) Nplate - product information. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/nplate-epar-product-information_en.pdf. Accessed 30th May 2022"},{"key":"5114_CR18","unstructured":"European Medicines Agency (EMA) Revolade - product information. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/revolade-epar-product-information_en.pdf. Accessed 30th May 2022"},{"key":"5114_CR19","unstructured":"European Medicines Agency (EMA) Doptolet - product information. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/doptelet-epar-product-information_en.pdf. Accessed 30th May 2022"},{"issue":"6","key":"5114_CR20","doi-asserted-by":"publisher","first-page":"e0198504","DOI":"10.1371\/journal.pone.0198504","volume":"13","author":"J Zhang","year":"2018","unstructured":"Zhang J, Liang Y, Ai Y, Li X, Xie J, Li Y, Zheng W, He R (2018) Eltrombopag versus romiplostim in treatment of adult patients with immune thrombocytopenia: a systematic review incorporating an indirect-comparison meta-analysis. PLoS One 13(6):e0198504. https:\/\/doi.org\/10.1371\/journal.pone.0198504","journal-title":"PLoS One"},{"issue":"1","key":"5114_CR21","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1002\/rth2.12457","volume":"5","author":"A Cuker","year":"2020","unstructured":"Cuker A, Despotovic JM, Grace RF, Kruse C, Lambert MP, Liebman HA, Lyons RM, McCrae KR, Pullarkat V, Wasser JS, Beenhouwer D, Gibbs SN, Yermilov I, Broder MS (2020) Tapering thrombopoietin receptor agonists in primary immune thrombocytopenia: expert consensus based on the RAND\/UCLA modified Delphi panel method. Res Pract Thromb Haemost 5(1):69\u201380. https:\/\/doi.org\/10.1002\/rth2.12457","journal-title":"Res Pract Thromb Haemost"},{"key":"5114_CR22","unstructured":"Howick J, Chalmers I, Glasziou P, Greenhalgh T, Heneghan C, Liberati A, Moschetti I, Phillips B, Thornton H Explanation of the 2011 Oxford Centre for Evidence-Based Medicine (OCEBM) Levels of Evidence (Background Document). Oxford Centre for Evidence-Based Medicine. https:\/\/www.cebm.ox.ac.uk\/resources\/levels-of-evidence\/explanation-of-the-2011-ocebm-levels-of-evidence. Accessed August 2022"},{"issue":"7650","key":"5114_CR23","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","volume":"336","author":"GH Guyatt","year":"2008","unstructured":"Guyatt GH (2008) GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 336(7650):924\u2013926. https:\/\/doi.org\/10.1136\/bmj.39489.470347.AD","journal-title":"BMJ"},{"issue":"7","key":"5114_CR24","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1080\/13611260500069947","volume":"27","author":"MR de Villiers","year":"2005","unstructured":"de Villiers MR, de Villiers PJT, Kent AP (2005) The Delphi technique in health sciences education research. Med Teach 27(7):639\u2013643. https:\/\/doi.org\/10.1080\/13611260500069947","journal-title":"Med Teach"},{"issue":"1","key":"5114_CR25","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1182\/asheducation-2018.1.568","volume":"2018","author":"CE Neunert","year":"2018","unstructured":"Neunert CE, Cooper N (2018) Evidence-based management of immune thrombocytopenia: ASH guideline update. Hematology 2018(1):568\u2013575. https:\/\/doi.org\/10.1182\/asheducation-2018.1.568","journal-title":"Hematology"},{"issue":"2","key":"5114_CR26","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1080\/09537104.2020.1745168","volume":"32","author":"S Birocchi","year":"2021","unstructured":"Birocchi S, Podda GM, Manzoni M, Casazza G, Cattaneo M (2021) Thrombopoietin receptor agonists for the treatment of primary immune thrombocytopenia: a meta-analysis and systematic review. Platelets 32(2):216\u2013226. https:\/\/doi.org\/10.1080\/09537104.2020.1745168","journal-title":"Platelets"},{"issue":"12","key":"5114_CR27","doi-asserted-by":"publisher","first-page":"2879","DOI":"10.1007\/s00277-021-04669-8","volume":"100","author":"I Cohen","year":"2021","unstructured":"Cohen I, Goldvaser H, Kirgner I, Leader A, Raanani P, Isakov O, Shepshelovich D (2021) Targeted therapies for immune thrombocytopenic purpura: a meta-analysis of randomized controlled trials. Ann Hematol 100(12):2879\u20132887. https:\/\/doi.org\/10.1007\/s00277-021-04669-8","journal-title":"Ann Hematol"},{"key":"5114_CR28","doi-asserted-by":"publisher","first-page":"704093","DOI":"10.3389\/fphar.2021.704093","volume":"12","author":"J Deng","year":"2021","unstructured":"Deng J, Hu H, Huang F, Huang C, Huang Q, Wang L, Wu A, Yang J, Qin D, Zou W, Wu J (2021) Comparative efficacy and safety of thrombopoietin receptor agonists in adults with thrombocytopenia: a systematic review and network meta-analysis of randomized controlled trial. Front Pharmacol 12:704093. https:\/\/doi.org\/10.3389\/fphar.2021.704093","journal-title":"Front Pharmacol"},{"key":"5114_CR29","doi-asserted-by":"publisher","first-page":"3113","DOI":"10.1007\/s12325-021-01752-4","volume":"38","author":"P Wojciechowski","year":"2021","unstructured":"Wojciechowski P, Wilson K, Nazir J, Pustu\u0142ka I, Tytu\u0142a A, Smela B, Pochopie\u0144 M, Vredenburg M, McCrae KR, Jurczak W (2021) Efficacy and safety of avatrombopag in patients with chronic immune thrombocytopenia: a systematic literature review and network meta-analysis. Adv Ther 38:3113\u20133128. https:\/\/doi.org\/10.1007\/s12325-021-01752-4","journal-title":"Adv Ther"},{"issue":"1","key":"5114_CR30","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1080\/16078454.2019.1568659","volume":"24","author":"R Yang","year":"2019","unstructured":"Yang R, Lin L, Yao H, Ji O, Shen Q (2019) Therapeutic options for adult patients with previously treated immune thrombocytopenia - a systematic review and network meta-analysis. Hematology 24(1):290\u2013299. https:\/\/doi.org\/10.1080\/16078454.2019.1568659","journal-title":"Hematology"},{"key":"5114_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/20406207211048361","volume":"12","author":"M Carpenedo","year":"2021","unstructured":"Carpenedo M, Baldacci E, Barat\u00e8 C, Borchiellini A, Buccisano F, Calvaruso G, Chiurazzi F, Fattizzo B, Giuffrida G, Rossi E, Palandri F, Scalzulli PR, Siragusa SM, Vitucci A, Zaja F (2021) Second-line administration of thrombopoietin receptor agonists in immune thrombocytopenia: Italian Delphi-based consensus recommendations. Ther Adv Hematol 12:1\u20139. https:\/\/doi.org\/10.1177\/20406207211048361","journal-title":"Ther Adv Hematol"},{"issue":"4","key":"5114_CR32","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1007\/s12185-017-2275-4","volume":"106","author":"TJ Gonz\u00e1lez-L\u00f3pez","year":"2017","unstructured":"Gonz\u00e1lez-L\u00f3pez TJ, Fern\u00e1ndez-Fuertes F, Hern\u00e1ndez-Rivas JA, S\u00e1nchez-Gonz\u00e1lez B, Mart\u00ednez-Robles V, Alvarez-Rom\u00e1n MT, P\u00e9rez-Rus G, Pascual C, Bernat S, Arrieta-Cerd\u00e1n E, Aguilar C, B\u00e1rez A, Pe\u00f1arrubia MJ, Olivera P, Fern\u00e1ndez-Rodr\u00edguez A, de Cabo E, Garc\u00eda-Frade LJ, Gonz\u00e1lez-Porras JR (2017) Efficacy and safety of eltrombopag in persistent and newly diagnosed ITP in clinical practice. Int J Hematol 106(4):508\u2013516. https:\/\/doi.org\/10.1007\/s12185-017-2275-4","journal-title":"Int J Hematol"},{"issue":"1","key":"5114_CR33","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1080\/16078454.2021.1974203","volume":"26","author":"O Meyer","year":"2021","unstructured":"Meyer O, Richter H, Lebioda A, Schill M (2021) Treatment patterns in adults with immune thrombocytopenia before, during and after use of thrombopoietin receptor agonists: a longitudinal prescription database study from Germany. Hematology 26(1):697\u2013708. https:\/\/doi.org\/10.1080\/16078454.2021.1974203","journal-title":"Hematology"},{"issue":"4","key":"5114_CR34","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1097\/mbc.0000000000000726","volume":"29","author":"ME Mingot-Castellano","year":"2018","unstructured":"Mingot-Castellano ME, Caparr\u00f3s IS, Fern\u00e1ndez F, Perera-Alvarez MDM, Jimenez-B\u00e1rcenas R, Casaus Garc\u00eda A, Gonz\u00e1lez-Silva M, Yera-Cobo M, Nieto-Hernandez MM, Rodr\u00edguez-Fernandez MJ, D\u00edaz-Canales D (2018) Treatment characteristics, efficacy and safety of thrombopoietin analogues in routine management of primary immune thrombocytopenia. Blood Coagul Fibrinolysis 29(4):374\u2013380. https:\/\/doi.org\/10.1097\/mbc.0000000000000726","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"3","key":"5114_CR35","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1111\/bjh.15803","volume":"185","author":"DJ Kuter","year":"2019","unstructured":"Kuter DJ, Newland A, Chong BH, Rodeghiero F, Romero MT, Pabinger I, Chen Y, Wang K, Mehta B, Eisen M (2019) Romiplostim in adult patients with newly diagnosed or persistent immune thrombocytopenia (ITP) for up to 1 year and in those with chronic ITP for more than 1 year: a subgroup analysis of integrated data from completed romiplostim studies. Br J Haematol 185(3):503\u2013513. https:\/\/doi.org\/10.1111\/bjh.15803","journal-title":"Br J Haematol"},{"issue":"4","key":"5114_CR36","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1007\/s12185-014-1533-y","volume":"99","author":"AK Tripathi","year":"2014","unstructured":"Tripathi AK, Shukla A, Mishra S, Yadav YS, Yadav DK (2014) Eltrombopag therapy in newly diagnosed steroid non-responsive ITP patients. Int J Hematol 99(4):413\u2013417. https:\/\/doi.org\/10.1007\/s12185-014-1533-y","journal-title":"Int J Hematol"},{"issue":"2","key":"5114_CR37","doi-asserted-by":"publisher","first-page":"E40","DOI":"10.1002\/ajh.26404","volume":"97","author":"G Moulis","year":"2022","unstructured":"Moulis G, Germain J, Rueter M, Lafaurie M, Aroichane M, Comont T, Mah\u00e9vas M, Viallard JF, Ch\u00e8ze S, Ebbo M, Audia S, Leclerc-Teffahi S, Sommet A, Beyne-Rauzy O, Michel M, Godeau B, Lapeyre-Mestre M (2022) Eltrombopag in adult patients with immune thrombocytopenia in the real-world in France, including off-label use before 6 months of disease duration: the multicenter, prospective ELEXTRA study. Am J Hematol 97(2):E40-e44. https:\/\/doi.org\/10.1002\/ajh.26404","journal-title":"Am J Hematol"},{"issue":"2","key":"5114_CR38","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1111\/bjh.13827","volume":"172","author":"A Newland","year":"2016","unstructured":"Newland A, Godeau B, Priego V, Viallard JF, L\u00f3pez Fern\u00e1ndez MF, Orejudos A, Eisen M (2016) Remission and platelet responses with romiplostim in primary immune thrombocytopenia: final results from a phase 2 study. Br J Haematol 172(2):262\u2013273. https:\/\/doi.org\/10.1111\/bjh.13827","journal-title":"Br J Haematol"},{"issue":"5","key":"5114_CR39","doi-asserted-by":"publisher","first-page":"2673","DOI":"10.1007\/s12325-021-01727-5","volume":"38","author":"SJ Snell Taylor","year":"2021","unstructured":"Snell Taylor SJ, Nielson CM, Breskin A, Saul B, Yu Y, Alam N, Eisen M, Hippenmeyer J, Janssens A, Kozak T, Papadaki HA, Selleslag D, Viallard JF, Feistritzer C, Kaiafa G, Kelsh M, Kilpatrick K, Brookhart MA, McGrath LJ (2021) Effectiveness and safety of romiplostim among patients with newly diagnosed, persistent and chronic immune thrombocytopenia in European clinical practice. Adv Ther 38(5):2673\u20132688. https:\/\/doi.org\/10.1007\/s12325-021-01727-5","journal-title":"Adv Ther"},{"issue":"12","key":"5114_CR40","doi-asserted-by":"publisher","first-page":"664","DOI":"10.3949\/ccjm.88a.20201","volume":"88","author":"S DeSouza","year":"2021","unstructured":"DeSouza S, Angelini D (2021) Updated guidelines for immune thrombocytopenic purpura: expanded management options. Clevel Clin J Med 88(12):664\u2013668. https:\/\/doi.org\/10.3949\/ccjm.88a.20201","journal-title":"Clevel Clin J Med"},{"issue":"Suppl 5","key":"5114_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000492187","volume":"41","author":"A Matzdorff","year":"2018","unstructured":"Matzdorff A, Meyer O, Ostermann H, Kiefel V, Eberl W, K\u00fchne T, Pabinger I, Rummel M (2018) Immune thrombocytopenia - current diagnostics and therapy: recommendations of a Joint Working Group of DGHO, \u00d6GHO, SGH, GPOH, and DGTI. Oncol Res Treat 41(Suppl 5):1\u201330. https:\/\/doi.org\/10.1159\/000492187","journal-title":"Oncol Res Treat"},{"issue":"1","key":"5114_CR42","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1111\/bjh.13266","volume":"169","author":"JR Gonz\u00e1lez-Porras","year":"2015","unstructured":"Gonz\u00e1lez-Porras JR, Mingot-Castellano ME, Andrade MM, Alonso R, Caparr\u00f3s I, Arratibel MC, Fern\u00e1ndez-Fuertes F, Cortti MJ, Pascual C, S\u00e1nchez-Gonz\u00e1lez B, Bernat S, Fuertes-Palacio MA, V\u00e1zquez-Paganini JA, Olivera PE, Alvarez-Rom\u00e1n MT, Jarque I, Cort\u00e9s M, Mart\u00ednez-Robles V, D\u00edaz-G\u00e1lvez FJ, Calbacho M, Fern\u00e1ndez-Mi\u00f1ano C, Garcia-Frade J, Gonz\u00e1lez-L\u00f3pez TJ (2015) Use of eltrombopag after romiplostim in primary immune thrombocytopenia. Br J Haematol 169(1):111\u2013116. https:\/\/doi.org\/10.1111\/bjh.13266","journal-title":"Br J Haematol"},{"issue":"1","key":"5114_CR43","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1002\/ajh.24935","volume":"93","author":"S Cantoni","year":"2018","unstructured":"Cantoni S, Carpenedo M, Mazzucconi MG, De Stefano V, Carrai V, Ruggeri M, Specchia G, Vianelli N, Pane F, Consoli U, Artoni A, Zaja F, D\u2019Adda M, Visentin A, Ferrara F, Barcellini W, Caramazza D, Baldacci E, Rossi E, Ricco A, Ciminello A, Rodeghiero F, Nichelatti M, Cairoli R (2018) Alternate use of thrombopoietin receptor agonists in adult primary immune thrombocytopenia patients: a retrospective collaborative survey from Italian hematology centers. Am J Hematol 93(1):58\u201364. https:\/\/doi.org\/10.1002\/ajh.24935","journal-title":"Am J Hematol"},{"issue":"6","key":"5114_CR44","doi-asserted-by":"publisher","first-page":"881","DOI":"10.3324\/haematol.2012.074633","volume":"98","author":"M Khellaf","year":"2013","unstructured":"Khellaf M, Viallard JF, Hamidou M, Cheze S, Roudot-Thoraval F, Lefrere F, Fain O, Audia S, Abgrall JF, Michot JM, Dauriac C, Lefort S, Gyan E, Niault M, Durand JM, Languille L, Boutboul D, Bierling P, Michel M, Godeau B (2013) A retrospective pilot evaluation of switching thrombopoietic receptor-agonists in immune thrombocytopenia. Haematologica 98(6):881\u2013887. https:\/\/doi.org\/10.3324\/haematol.2012.074633","journal-title":"Haematologica"},{"issue":"4","key":"5114_CR45","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1111\/ejh.12932","volume":"99","author":"S Lakhwani","year":"2017","unstructured":"Lakhwani S, Perera M, Fern\u00e1ndez-Fuertes F, R\u00edos de Paz MA, Torres M, Raya JM, Hern\u00e1ndez MT (2017) Thrombopoietin receptor agonist switch in adult primary immune thrombocytopenia patients: a retrospective collaborative survey involving 4 Spanish centres. Eur J Haematol 99(4):372\u2013377. https:\/\/doi.org\/10.1111\/ejh.12932","journal-title":"Eur J Haematol"},{"issue":"3","key":"5114_CR46","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1111\/bjh.18081","volume":"197","author":"H Al-Samkari","year":"2022","unstructured":"Al-Samkari H, Jiang D, Gernsheimer T, Liebman H, Lee S, Wojdyla M, Vredenburg M, Cuker A (2022) Adults with immune thrombocytopenia who switched to avatrombopag following prior treatment with eltrombopag or romiplostim: a multicentre US study. Br J Haematol 197(3):359\u2013366. https:\/\/doi.org\/10.1111\/bjh.18081","journal-title":"Br J Haematol"},{"issue":"3","key":"5114_CR47","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/s12185-014-1731-7","volume":"101","author":"DJ Kuter","year":"2015","unstructured":"Kuter DJ, Macahilig C, Grotzinger KM, Poston SA, Wang PF, Dawson KL, Ward M (2015) Treatment patterns and clinical outcomes in patients with chronic immune thrombocytopenia (ITP) switched to eltrombopag or romiplostim. Int J Hematol 101(3):255\u2013263. https:\/\/doi.org\/10.1007\/s12185-014-1731-7","journal-title":"Int J Hematol"},{"issue":"4","key":"5114_CR48","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1159\/000510676","volume":"144","author":"N Cooper","year":"2021","unstructured":"Cooper N, Hill QA, Grainger J, Westwood JP, Bradbury C, Provan D, Thachil J, Ramscar N, Roy A (2021) Tapering and discontinuation of thrombopoietin receptor agonist therapy in patients with immune thrombocytopenia: results from a modified Delphi panel. Acta Haematol 144(4):418\u2013426. https:\/\/doi.org\/10.1159\/000510676","journal-title":"Acta Haematol"},{"issue":"3","key":"5114_CR49","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/j.clinthera.2012.01.011","volume":"34","author":"MB Wire","year":"2012","unstructured":"Wire MB, Bruce J, Gauvin J, Pendry CJ, McGuire S, Qian Y, Brainsky A (2012) A randomized, open-label, 5-period, balanced crossover study to evaluate the relative bioavailability of eltrombopag powder for oral suspension (PfOS) and tablet formulations and the effect of a high-calcium meal on eltrombopag pharmacokinetics when administered with or 2 hours before or after PfOS. Clin Ther 34(3):699\u2013709. https:\/\/doi.org\/10.1016\/j.clinthera.2012.01.011","journal-title":"Clin Ther"},{"issue":"8","key":"5114_CR50","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1056\/NEJMoa1110709","volume":"367","author":"NH Afdhal","year":"2012","unstructured":"Afdhal NH, Giannini EG, Tayyab G, Mohsin A, Lee JW, Andriulli A, Jeffers L, McHutchison J, Chen PJ, Han KH, Campbell F, Hyde D, Brainsky A, Theodore D (2012) Eltrombopag before procedures in patients with cirrhosis and thrombocytopenia. N Engl J Med 367(8):716\u2013724. https:\/\/doi.org\/10.1056\/NEJMoa1110709","journal-title":"N Engl J Med"},{"issue":"6","key":"5114_CR51","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1016\/j.jhep.2014.07.007","volume":"61","author":"NA Terrault","year":"2014","unstructured":"Terrault NA, Hassanein T, Howell CD, Joshi S, Lake J, Sher L, Vargas H, McIntosh J, Tang S, Jenkins TM (2014) Phase II study of avatrombopag in thrombocytopenic patients with cirrhosis undergoing an elective procedure. J Hepatol 61(6):1253\u20131259. https:\/\/doi.org\/10.1016\/j.jhep.2014.07.007","journal-title":"J Hepatol"},{"issue":"3","key":"5114_CR52","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1053\/j.gastro.2018.05.025","volume":"155","author":"N Terrault","year":"2018","unstructured":"Terrault N, Chen YC, Izumi N, Kayali Z, Mitrut P, Tak WY, Allen LF, Hassanein T (2018) Avatrombopag before procedures reduces need for platelet transfusion in patients with chronic liver disease and thrombocytopenia. Gastroenterology 155(3):705\u2013718. https:\/\/doi.org\/10.1053\/j.gastro.2018.05.025","journal-title":"Gastroenterology"},{"issue":"4","key":"5114_CR53","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1620\/tjem.240.277","volume":"240","author":"T Kurokawa","year":"2016","unstructured":"Kurokawa T, Murata S, Ohkohchi N (2016) Stable liver function during long-term administration of eltrombopag, a thrombopoietin receptor agonist, in patients with chronic liver disease. Tohoku J Exp Med 240(4):277\u2013279. https:\/\/doi.org\/10.1620\/tjem.240.277","journal-title":"Tohoku J Exp Med"},{"key":"5114_CR54","doi-asserted-by":"publisher","unstructured":"Flisiak R, Antonov K, Drastich P, Jarcuska P, Maevskaya M, Makara M, Puljiz \u017d, \u0160tabuc B, Trifan A (2021) Practice guidelines of the Central European Hepatologic Collaboration (CEHC) on the use of thrombopoietin receptor agonists in patients with chronic liver disease undergoing invasive procedures. J Clin Med 10(22):5419. https:\/\/doi.org\/10.3390\/jcm10225419","DOI":"10.3390\/jcm10225419"},{"issue":"1","key":"5114_CR55","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1097\/MBC.0000000000001109","volume":"33","author":"N Pantic","year":"2022","unstructured":"Pantic N, Suvajdzic-Vukovic N, Virijevic M, Pravdic Z, Sabljic N, Adzic-Vukicevic T, Mitrovic M (2022) Coronavirus disease 2019 in patients with chronic immune thrombocytopenia on thrombopoietin receptor agonists: new perspectives and old challenges. Blood Coag Fibrinol 33(1):51\u201355. https:\/\/doi.org\/10.1097\/MBC.0000000000001109","journal-title":"Blood Coag Fibrinol"},{"issue":"6","key":"5114_CR56","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1182\/bloodadvances.2021006379","volume":"6","author":"C Visser","year":"2022","unstructured":"Visser C, Swinkels M, van Werkhoven ED, Croles FN, Noordzij-Nooteboom HS, Eefting M, Last-Koopmans SM, Idink C, Westerweel PE, Santbergen B, Jobse PA, Baboe F, Consortium R-I, Te Boekhorst PAW, Leebeek FWG, Levin M-D, Kruip MJHA, Jansen AJG (2022) COVID-19 vaccination in patients with immune thrombocytopenia. Blood advances 6(6):1637\u20131644. https:\/\/doi.org\/10.1182\/bloodadvances.2021006379","journal-title":"Blood advances"},{"issue":"11","key":"5114_CR57","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.1002\/jmv.26251","volume":"92","author":"KK Sahu","year":"2020","unstructured":"Sahu KK, Siddiqui AD, Rezaei N, Cerny J (2020) Challenges for management of immune thrombocytopenia during COVID-19 pandemic. J Med Virol 92(11):2277\u20132282. https:\/\/doi.org\/10.1002\/jmv.26251","journal-title":"J Med Virol"},{"issue":"26","key":"5114_CR58","doi-asserted-by":"publisher","first-page":"3056","DOI":"10.1182\/blood.2020007594","volume":"136","author":"M Michel","year":"2020","unstructured":"Michel M, Ruggeri M, Gonzalez-Lopez TJ, Alkindi S, Cheze S, Ghanima W, Tvedt THA, Ebbo M, Terriou L, Bussel JB, Godeau B (2020) Use of thrombopoietin receptor agonists for immune thrombocytopenia in pregnancy: results from a multicenter study. Blood 136(26):3056\u20133061. https:\/\/doi.org\/10.1182\/blood.2020007594","journal-title":"Blood"},{"issue":"12","key":"5114_CR59","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1002\/ajh.25989","volume":"95","author":"Y Yu","year":"2020","unstructured":"Yu Y, Wang M, Hou Y, Qin P, Zeng Q, Yu W, Guo X, Wang J, Wang X, Liu G, Chu X, Yang L, Feng Y, Zhou F, Sun Z, Zhang M, Wang X, Wang Z, Ran X, Zhao H, Wang L, Zhang H, Bi K, Li D, Yuan C, Xu R, Wang Y, Zhou Y, Peng J, Liu XG, Hou M (2020) High-dose dexamethasone plus recombinant human thrombopoietin vs high-dose dexamethasone alone as frontline treatment for newly diagnosed adult primary immune thrombocytopenia: a prospective, multicenter, randomized trial. Am J Hematol 95(12):1542\u20131552. https:\/\/doi.org\/10.1002\/ajh.25989","journal-title":"Am J Hematol"},{"issue":"25","key":"5114_CR60","doi-asserted-by":"publisher","first-page":"3906","DOI":"10.1182\/blood-2014-01-549360","volume":"123","author":"D G\u00f3mez-Almaguer","year":"2014","unstructured":"G\u00f3mez-Almaguer D, Herrera-Rojas MA, Jaime-P\u00e9rez JC, G\u00f3mez-De Le\u00f3n A, Cant\u00fa-Rodr\u00edguez OG, Guti\u00e9rrez-Aguirre CH, Tar\u00edn-Arzaga L, Hern\u00e1ndez-Reyes J, Ruiz-Arguelles GJ (2014) Eltrombopag and high-dose dexamethasone as frontline treatment of newly diagnosed immune thrombocytopenia in adults. Blood 123(25):3906\u20133908. https:\/\/doi.org\/10.1182\/blood-2014-01-549360","journal-title":"Blood"},{"issue":"2","key":"5114_CR61","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1111\/bjh.16327","volume":"189","author":"L Zhang","year":"2020","unstructured":"Zhang L, Zhang M, Du X, Cheng Y, Cheng G (2020) Safety and efficacy of eltrombopag plus pulsed dexamethasone as first-line therapy for immune thrombocytopenia. Br J Haematol 189(2):369\u2013378. https:\/\/doi.org\/10.1111\/bjh.16327","journal-title":"Br J Haematol"},{"key":"5114_CR62","doi-asserted-by":"publisher","first-page":"100909","DOI":"10.1016\/j.blre.2021.100909","volume":"53","author":"DJ Kuter","year":"2022","unstructured":"Kuter DJ (2022) The structure, function, and clinical use of the thrombopoietin receptor agonist avatrombopag. Blood Rev 53:100909. https:\/\/doi.org\/10.1016\/j.blre.2021.100909","journal-title":"Blood Rev"},{"issue":"1","key":"5114_CR63","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1182\/asheducation-2017.1.144","volume":"2017","author":"DB Cines","year":"2017","unstructured":"Cines DB, Levine LD (2017) Thrombocytopenia in pregnancy. Hematology 2017(1):144\u2013151. https:\/\/doi.org\/10.1182\/asheducation-2017.1.144","journal-title":"Hematology"},{"key":"5114_CR64","doi-asserted-by":"publisher","unstructured":"Agarwal N, Mangla A (2021) Thrombopoietin receptor agonist for treatment of immune thrombocytopenia in pregnancy: a narrative review. Therapeutic Advances in Hematology 12:1\u201317. https:\/\/doi.org\/10.1177\/20406207211001139","DOI":"10.1177\/20406207211001139"},{"issue":"11","key":"5114_CR65","doi-asserted-by":"publisher","first-page":"2048","DOI":"10.1007\/s42399-020-00521-8","volume":"2","author":"S Bhattacharjee","year":"2020","unstructured":"Bhattacharjee S, Banerjee M (2020) Immune thrombocytopenia secondary to COVID-19: a systematic review. SN Compr Clin Med 2(11):2048\u20132058. https:\/\/doi.org\/10.1007\/s42399-020-00521-8","journal-title":"SN Compr Clin Med"},{"key":"5114_CR66","unstructured":"Berger B, Rodgers G (2021) ITP secondary to COVID-19: a comprehensive review of reported cases. Abstract PB0169. Presented at the ISTH; July 17\u201321, Philadelphia, PA. https:\/\/abstracts.isth.org\/abstract\/itp-secondary-to-covid-19-a-comprehensive-review-of-reported-cases\/"},{"issue":"6","key":"5114_CR67","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1111\/bjh.16775","volume":"189","author":"S Pavord","year":"2020","unstructured":"Pavord S, Thachil J, Hunt BJ, Murphy M, Lowe G, Laffan M, Makris M, Newland AC, Provan D, Grainger JD, Hill QA (2020) Practical guidance for the management of adults with immune thrombocytopenia during the COVID-19 pandemic. Br J Haematol 189(6):1038\u20131043. https:\/\/doi.org\/10.1111\/bjh.16775","journal-title":"Br J Haematol"},{"issue":"6","key":"5114_CR68","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1111\/bjh.16775","volume":"189","author":"S Pavord","year":"2020","unstructured":"Pavord S, Thachil J, Hunt BJ, Murphy M, Lowe G, Laffan M, Makris M, Newland AC, Provan D, Grainger JD, Hill QA (2020) Practical guidance for the management of adults with immune thrombocytopenia during the COVID-19 pandemic. Br J Haematol 189(6):1038\u20131043. https:\/\/doi.org\/10.1111\/bjh.16775","journal-title":"Br J Haematol"},{"issue":"1","key":"5114_CR69","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s40164-021-00235-0","volume":"10","author":"SRA Shah","year":"2021","unstructured":"Shah SRA, Dolkar S, Mathew J, Vishnu P (2021) COVID-19 vaccination associated severe immune thrombocytopenia. Exp Hematol Oncol 10(1):42. https:\/\/doi.org\/10.1186\/s40164-021-00235-0","journal-title":"Exp Hematol Oncol"},{"key":"5114_CR70","doi-asserted-by":"publisher","first-page":"39003","DOI":"10.1038\/srep39003","volume":"6","author":"L Wang","year":"2016","unstructured":"Wang L, Gao Z, Chen XP, Zhang HY, Yang N, Wang FY, Guan LX, Gu ZY, Zhao SS, Luo L, Wei HP, Gao CJ (2016) Efficacy and safety of thrombopoietin receptor agonists in patients with primary immune thrombocytopenia: a systematic review and meta-analysis. Sci Rep 6:39003. https:\/\/doi.org\/10.1038\/srep39003","journal-title":"Sci Rep"},{"issue":"6","key":"5114_CR71","doi-asserted-by":"publisher","first-page":"e12592","DOI":"10.1002\/rth2.12592","volume":"5","author":"A Cuker","year":"2021","unstructured":"Cuker A, Liebman HA (2021) Corticosteroid overuse in adults with immune thrombocytopenia: cause for concern. Res Pract Thromb Haemost 5(6):e12592\u2013e12592. https:\/\/doi.org\/10.1002\/rth2.12592","journal-title":"Res Pract Thromb Haemost"},{"issue":"5","key":"5114_CR72","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1179\/102453311X13025568942005","volume":"16","author":"M Michel","year":"2011","unstructured":"Michel M, te Boekhorst PAW, Janssens A, Pabinger-Fasching I, Sanz MA, Nie K, Kreuzbauer G (2011) Reduced corticosteroid use in adult patients with primary immune thrombocytopenia receiving romiplostim. Hematology (Amsterdam, Netherlands) 16(5):274\u2013277. https:\/\/doi.org\/10.1179\/102453311X13025568942005","journal-title":"Hematology (Amsterdam, Netherlands)"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-023-05114-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-023-05114-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-023-05114-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,29]],"date-time":"2024-08-29T06:05:12Z","timestamp":1724911512000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-023-05114-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,24]]},"references-count":72,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["5114"],"URL":"https:\/\/doi.org\/10.1007\/s00277-023-05114-8","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,24]]},"assertion":[{"value":"7 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 January 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"DP received honoraria as a member of advisory boards and\/or speaker from Novartis, Amgen, and Sobi; AB received honoraria as a member of advisory boards and speaker from Novartis and Sobi; II received honoraria as a member of advisory boards and\/or speaker from Novartis, Amgen, Pfizer, Roche, Takeda, Accord, and Sobi; TL has taken part as a Principle Investigator for projects financed by Bayer, CSL Behring, Catalist, Grifols, Octapharma, Pfizer, Sanofi-Alnilam, and Bioverativ, received honoraria as a member of advisory boards from Roche and Sobi, and has received honoraria as a lecturer from Novo Nordisk, Octapharma, Roche, and Sobi; IB declares no conflicts of interest; LC received honoraria as a member of advisory boards and\/or speaker from Novartis, Amgen, Alexion, and Sobi; AM received honoraria as a member of advisory boards from Novartis and Sobi and as a speaker from Novartis and Amgen; and M.P-D has received consulting and lecture fees from Alexion, Amgen, CSL-Behring, Novo Nordisk, Novartis, Orphan, Roche, Sanofi, Sobi, Swiss-Pharma, and Takeda and an institutional research grant from Takeda.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}